Sevierville

This research aims to determine if the Quest AD-Detect blood test can help diagnose underlying Alzheimer's disease earlier in patients hospitalized with cognitive issues such as delirium or encephalopathy. The study focuses on patients aged 60 to 90 who have no prior diagnosis of dementia but show cognitive impairment possibly related to toxic or metabolic conditions. Researchers want to see if the blood test can distinguish Alzheimer's disease from other causes of cognitive problems in the hospital setting. All eligible patients will have their blood collected and tested using the Quest AD-Detect blood test during their hospital stay. The study involves only one group where every participant receives this diagnostic blood test. There are no placebo or comparison groups in this trial. Participants will be followed up for six months after hospitalization through a Neurology Clinic to discuss their risk assessment results. The main outcome measured is the percentage of patients with a positive biomarker for Alzheimer's dementia among those presenting with cognitive diagnoses. The trial's total duration extends from enrollment to the six-month post-hospital follow-up visit.